Evernorth, the Cigna Group’s health services arm, will cap out-of-pocket costs for Zepbound and Wegovy, two GLP-1 drugs, at $200.
Members can save up to $3,600 a year compared to purchasing the drugs directly or through consumer programs, according to a May 21 news release.
Here are five things to know:
- Evernorth negotiated with the medications’ manufacturers to reach the copay cap.
- The company will also implement easier prior authorization processes for Wegovy and Zepbound, according to the release.
- Health plan sponsors will see a significant decrease in the cost per prescription of the drugs, Evernorth said.
- Wegovy and Zepbound, GLP-1 drugs approved for weight loss, can cost upwards of $1,000 a month without insurance.
- Cigna has implemented several other programs designed to manage the cost of weight loss drugs. In 2024, the company launched EncircleRx, a financial model to cap the costs of GLP-1s for employers. The program has grown to 9 million members.
